By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ampio Pharmaceuticals, Inc. 

5445 DTC Parkway, P4

Greenwood Village  Colorado  80111  U.S.A.
Phone: 303-418-1000 Fax: 303-418-1001


SEARCH JOBS


Industry
Pharmaceutical






Company News
Letter To The Ampio Pharmaceuticals, Inc. (AMPE) Shareholders In Regard To The STEP Study And Ampio's Plans For The Ampion™ BLA 8/25/2014 10:19:48 AM
Ampio Pharmaceuticals, Inc. (AMPE) Reports That Due To Temperature Deviations Below Product Specifications During Shipments To The Ampion™ STEP Study Clinical Sites, Release Of Data Will Be Delayed 8/21/2014 7:32:26 AM
Ampio Pharmaceuticals, Inc. (AMPE) Release: Analysis Of Available Data From Optimeyes Study (Blinded And Open Label) Of Optina™ For The Treatment Of Diabetic Macular Edema (DME) Indicates Potential For Significant Clinical Benefit 8/20/2014 7:31:30 AM
Ampio Pharmaceuticals, Inc. (AMPE) Touts Very Positive Data For Ampion Osteoarthrtis Study 8/18/2014 6:20:52 AM
Ampio Pharmaceuticals, Inc. (AMPE) Updates On Positive One-Month Results From Ampion Open Label Study 8/5/2014 6:56:25 AM
Ampio Pharmaceuticals, Inc. (AMPE) Announces The FDA Has Issued A Written Response And Accepted The Ampio Plan For Beginning Production Of Ampion™ In The New Facility 7/30/2014 8:12:48 AM
Ampio Pharmaceuticals, Inc. (AMPE) Announces The Opening Of Its New Headquarters, Manufacturing And Research Facility In Englewood Colorado 7/23/2014 10:51:14 AM
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014 8:47:00 AM
Due To Positive Feedback, Ampio Pharmaceuticals, Inc. (AMPE) Closes Enrollment Of OptimEyes Study, Will Present Data To FDA For Guidance 6/25/2014 6:18:48 AM
Ampio Pharmaceuticals, Inc. (AMPE) Announces Appointment Of Gregory A. Gould As Chief Financial Officer 6/5/2014 7:16:18 AM
12345678910...
//-->